Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16)
In newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved outcomes when added to the standard-of-care regimens. In a randomized trial, we tested whether similar improvements would be observed when daratumumab was added to the bortezomib, cyclophosphamide, and dexametha...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 语言: | 英语 |
| 出版: |
2024
|
| 在线阅读: | https://doi.org/10.1182/bloodadvances.2023012539 https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023012539/2225304/bloodadvances.2023012539.pdf |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|